MX2025005318A - Compuesto de cucurbiturilo y uso medico del mismo - Google Patents
Compuesto de cucurbiturilo y uso medico del mismoInfo
- Publication number
- MX2025005318A MX2025005318A MX2025005318A MX2025005318A MX2025005318A MX 2025005318 A MX2025005318 A MX 2025005318A MX 2025005318 A MX2025005318 A MX 2025005318A MX 2025005318 A MX2025005318 A MX 2025005318A MX 2025005318 A MX2025005318 A MX 2025005318A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- medical use
- present disclosure
- disclosure relates
- cucurbituril compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
La presente descripción se refiere a un compuesto de cucurbiturilo y el uso médico del mismo. Específicamente, la presente descripción se refiere a un compuesto como se muestra en la fórmula (I), una sal farmacéuticamente aceptable del mismo, un método de preparación del mismo, una composición farmacéutica que comprende el mismo y el uso del mismo como un agente terapéutico, en particular el uso del mismo en el tratamiento o prevención de enfermedades proliferativas, enfermedades relacionadas con cardiovascular o cáncer de sangre y el uso del mismo en la reversión de bloqueo neuromuscular inducido por fármacos y/o anestesia, en donde cada sustituyente es como se define en la descripción. (I) (Ver Fórmula (I)).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211412397 | 2022-11-11 | ||
| CN202310888540 | 2023-07-19 | ||
| PCT/CN2023/131007 WO2024099434A1 (zh) | 2022-11-11 | 2023-11-10 | 葫芦脲类化合物及其医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025005318A true MX2025005318A (es) | 2025-06-02 |
Family
ID=91031981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025005318A MX2025005318A (es) | 2022-11-11 | 2025-05-07 | Compuesto de cucurbiturilo y uso medico del mismo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260167624A1 (es) |
| EP (1) | EP4617274A4 (es) |
| JP (1) | JP2025541968A (es) |
| KR (1) | KR20250102033A (es) |
| CN (1) | CN120019057A (es) |
| AU (1) | AU2023378470A1 (es) |
| MX (1) | MX2025005318A (es) |
| TW (1) | TW202421155A (es) |
| WO (1) | WO2024099434A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119613419A (zh) * | 2023-09-13 | 2025-03-14 | 中国科学院上海有机化学研究所 | 氘代的二芳基甘脲四聚体化合物及其用途 |
| WO2025237335A1 (zh) * | 2024-05-14 | 2025-11-20 | 江苏恒瑞医药股份有限公司 | 一种葫芦脲衍生物的可药用盐、其结晶形式及用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100400085B1 (ko) * | 2001-07-04 | 2003-09-29 | 학교법인 포항공과대학교 | 수용성 및 지용성 쿠커비투릴 유도체, 그 제조방법, 그분리방법 및 용도 |
| US9566351B2 (en) * | 2010-10-13 | 2017-02-14 | University Of Maryland, College Park | Molecular containers and methods of making and using same |
| WO2012051407A2 (en) | 2010-10-13 | 2012-04-19 | University Of Maryland, College Park | Molecular containers and methods of making and using same |
| EP3207046B1 (en) * | 2014-10-18 | 2024-09-25 | University of Maryland, College Park | Acyclic cucurbit(n)uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders |
| WO2022206086A1 (zh) * | 2021-04-19 | 2022-10-06 | 张振涛 | 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用 |
| CN116925087A (zh) * | 2023-07-18 | 2023-10-24 | 复旦大学 | 一类二芳基四甘脲羧酸盐及其用途 |
| CN116925088A (zh) * | 2023-07-21 | 2023-10-24 | 复旦大学 | 二芳并四甘脲八羧酸盐及其用途 |
-
2023
- 2023-11-10 US US19/128,787 patent/US20260167624A1/en active Pending
- 2023-11-10 EP EP23888119.7A patent/EP4617274A4/en active Pending
- 2023-11-10 JP JP2025525356A patent/JP2025541968A/ja active Pending
- 2023-11-10 TW TW112143509A patent/TW202421155A/zh unknown
- 2023-11-10 CN CN202380072472.5A patent/CN120019057A/zh active Pending
- 2023-11-10 AU AU2023378470A patent/AU2023378470A1/en active Pending
- 2023-11-10 KR KR1020257015049A patent/KR20250102033A/ko active Pending
- 2023-11-10 WO PCT/CN2023/131007 patent/WO2024099434A1/zh not_active Ceased
-
2025
- 2025-05-07 MX MX2025005318A patent/MX2025005318A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4617274A1 (en) | 2025-09-17 |
| US20260167624A1 (en) | 2026-06-18 |
| JP2025541968A (ja) | 2025-12-24 |
| TW202421155A (zh) | 2024-06-01 |
| CN120019057A (zh) | 2025-05-16 |
| KR20250102033A (ko) | 2025-07-04 |
| AU2023378470A1 (en) | 2025-06-05 |
| EP4617274A4 (en) | 2026-03-18 |
| WO2024099434A1 (zh) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025001700A (es) | Compuestos triciclicos y uso medico de los mismos | |
| MX2025001619A (es) | Inhibidor de pde4b y uso del mismo | |
| CA2501651A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| EP2533785B1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| AU2021311245A8 (en) | Compound for androgen receptor degradation, and pharmaceutical use thereof | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| MX2025013245A (es) | Compuesto de camptotecina deuterado, preparacion y uso de este | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| IL317168A (en) | GCN2 modulator for cancer treatment | |
| MX2025011458A (es) | Inhibidor de cyp11a1 y uso del mismo | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| EP4494700A3 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| MX2024014994A (es) | Macrociclos de indazol y su uso | |
| MX2023014131A (es) | Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo. | |
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo | |
| MX2023006193A (es) | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
| MX2026002937A (es) | Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos |